On December 20, 2021 Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, reported that the company will present at two upcoming scientific meetings, the AACR (Free AACR Whitepaper) Special Conference: Targeting RAS, being held January 7-10, 2022 in Lake Buena Vista, Florida and the ASCO (Free ASCO Whitepaper) GI Cancers Symposium, being held January 20-22 in San Francisco, California (Press release, Kinnate Biopharma, DEC 20, 2021, View Source [SID1234597455]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Since our founding, Kinnate has been driven by our mission to expand the availability of targeted therapies to all patients who may benefit from them," said Richard Williams, MBBS, Ph.D., Chief Medical Officer at Kinnate. "We are very pleased with the continued progress of both our RAF and FGFR inhibitor programs and look forward to sharing these updates with the oncology community at these upcoming meetings."
Details of the upcoming AACR (Free AACR Whitepaper) Special Conference: Targeting RAS presentation, which will be delivered by Paul Severson, Ph.D., Kinnate’s Senior Director of Translational Medicine and Bioinformatics, are as follows:
Abstract title: Real-World Clinico-Genomic Analysis of Patients with BRAF Mutated Solid Tumors Identifies BRAF Class II and III as a Significant Population of Unmet Need
Session: Poster Session A
Session date and time: Saturday, January 8, 2022, from 4:45PM -7:00PM ET
Additional information on the AACR (Free AACR Whitepaper) Special Conference: Targeting RAS is available through the conference website at: View Source
Details of the upcoming ASCO (Free ASCO Whitepaper) GI Cancers Symposium presentation, which will be delivered by Aleksandra Franovic, Ph.D., Senior Director of Translational Medicine at Kinnate, are as follows:
Abstract title: Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations
Session: Poster Session B
Session date and time: Friday, January 21, 2022, from 3:05PM – 4:35PM ET
Additional information on the ASCO (Free ASCO Whitepaper) GI Cancers Symposium is available through the conference website at: View Source